NCT06800404View on ClinicalTrials.gov

"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 2, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Relapsing Remitting Multiple Sclerosis (RRMS)Multiple Sclerosis
Interventions
DRUG

Autologous HB-adMSCs

Autologous HB-adMSCs

Trial Locations (1)

77479

Hope Biosciences Research Foundation, Sugar Land

All Listed Sponsors
lead

Hope Biosciences Research Foundation

INDUSTRY

NCT06800404 - "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" | Biotech Hunter | Biotech Hunter